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Detection of Quinolones Resistant among Gram Negative Bacteria Isolated From Clinical Specimens  PROF. DR. YAHYA A .ABBAS1      MOHAMMED MAHDI ABD2 1.AL-Nasiriyiah Technical Institute 2.Department of Biology  .College of Science.Uuniversity of  Thi-Qar  Abstract  The study was conducted through a period from November 2015 to may 2016, a total of 316 samples from various clinical cases of different patients were randomly collected and examined for detection of Gram negative bacteria .These clinical samples included wound swabs, burn swabs, ear swabs, sputum samples, stool, all collected samples were screened for presence of Gram negative bacteria by culturing on appropriate media and 94 Gram negative bacteria were identified via biochemical tests and confirmed by API 20E system. Overall, qnr-genes  ( quinolones resistance genes ) were detected by multiplex PCR technique in 28/94 (29.78%) of all clinical isolates. However, the results showed that quinolones-resistance genes gave 25 positive results for qnrB, while 9 positive results for qnrS, but qnrA gene was not detected in any of the clinical isolates. Keywords: Gram negative bacteria, Antibiotics and qnr genes  INTRODUCTION Quinolones act by inhibiting the action of type II topoisomerases, DNA gyrase and topoisomerase IV (Gellert et al., 1977). Quinolones are broad-spectrum antibacterial agents, commonly used in both clinical and veterinary medicine. Their extensive use has resulted in bacteria rapidly developing resistance to these agents. Two mechanisms of quinolone resistance have been established to date: alterations in the targets of quinolones, and decreased accumulation due to impermeability of the membrane and/or an overexpression of efflux pump systems. Recently, mobile elements have also been described, carrying the qnr gene (quinolone-resistance genes), which confers resistance to quinolones (Joaquim Ruiz, 2003). Recently, a plasmid in Klebsiella pneumoniae has been described, capable of conferring quinolone resistance when transferred to a recipient strain (Martínez-Martínez et al.,1998). Tran and Jacoby, (2002) they reported that the plasmid contains a novel gene, which they named qnr, that encodes a protein of 218 amino acids belonging to the pentapeptide repeat family. The product of this gene protects the DNA gyrase from quinolone inhibition, although its effect on topoisomerase IV is unclear. In vitro studies demonstrated that Qnr protected the E. coli DNA gyrase from inhibition by ciprofloxacin but did not protect topoisomerase IV (Tran et al, 2005). Further molecular studies demonstrated that qnr was collocated with other resistance determinants on sul1-type integrons (Rodríguez-Martinez et al, 2007). The presence of qnr has frequently been found in strains producing extended spectrum β-lactamases (Hata et al, 2005). Three qnr genes have been detected, qnrA gene, qnrS, and qnrB gene (Jacoby et al., 2003; Hata et al., 2005 ; Cattoir et al., 2008). Qnr determinants have then been identified globaly (Touati et al., 2008). Some reports proposed that this plasmid-mediated mechanism was broadly distributed and was detected in all clinically related bacteria from Enterobacteriaceae family (Cheung et al., 2005; Jeong et al., 2005). These genes have been detected in some non-fermenting Gram-negative like qnrS gene has been detected in Aeromonas spp isolated from both clinical and environment samples (Nazik et al., 2005;Cattoir et al., 2008; Sánchez et al., 2008). The aim of the present study is to detection some quinolones resistance genes (qnrA gene, qnrS, and qnrB gene) in Gram negative bacteria isolated from clinical samples and the antibiotic profile of these bacteria.  MATERIALS AND METHODS The study was conducted through a period from November 2015 to may 2016, samples collected from patients retened /or admitted to Al Hussein Teaching Hospitals and Public Health Laboratory in Thi-Qar province. A total of 316 non-duplicate samples from various clinical of different patients were randomly collected and examined for detection of Gram negative bacteria. The results showed 94 (29.74%) of samples gave positive for microbial infection by Gram negative. These clinical samples included wound swab (n=56, 17.7%), burn swab (n=52,16.4% ), ear swab (n=87,27.5% ) sputum (n=34, 10.7%), stool samples (n=44,13.9%) urine of patients with U.T.I (n= 43, 13.6%). Isolation and identification of bacterial isolates , all specimens were cultured on blood agar and MacConkey agar and incubated overnight at 37°C under aerobic conditions. Depending on morphological features of colonies and microscopical examination with Gram stain then biochemical tests were used to differentiate among Gram negative bacteria. Diagnosis of species was confirmed by API 20E system. Antibiotic susceptibility test, susceptibility tests were performed for all bacterial isolates against 17 antimicrobial agent (Bioanalyse, Turkey) from different classes have been determined using kirby-Bauer disc 
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diffusion method (Bauer et al.,1966). Inhibition zone around antibiotic discs was measured as in CLSI guidelines (2014) . The agents tested included amikacin (AK: 30 µg), ceftriaxone (CRO: 30 µg), ciprofloxacin (CIP: 5 µg), gentamicin (CN: 10 µg), imipenem (IMP: 10 µg), meropenem (MEM: 10 µg), cefotaxime (CTX: 30 µg), ceftazidime (CAZ: 30 µg ), amoxicillin (AX: 10 µg ),amoxicillin - clavulanic acid (AUG:30 µg) norfloxacin (NOR:10 µg) ,naldixic acid (NA:30 µg) ,netilmicin (NET:30 µg) ,ticarcillin (TI:75 µg) , nitrofurantion (F:300 µg) , carbencillin (PY:100 µg) and aztreonam (AT:30 µg).  MULTIPLEX PCR TECHNIQUE  Pure colonies of the clinical isolates were used for DNA extraction ( using kit of Geneaid, England). Primers of the qnrA-, qnrB- and qnrS-like genes, which designed by cattoir et al.,2007 were used with sizes of 580, 264 and 428 bp, respectively. A pair of degenerated primers was specifically designed to amplify the six variants of qnrB, despite the high polymorphism of this gene. Total DNA (2 µL) was subjected to multiplex PCR in a 50 µL reaction mixture containing 1X PCR buffer [10 mM Tris–HCl (pH 8.3), 50 mM KCl], 1.5 mM MgCl2, 200 mM each deoxynucleotide triphosphate, 20 pmol of each of the six primers and 2.5 U of Taq polymerase. Amplification was carried out with the following thermal cycling profile: 10 min at 95°C and 35 cycles of amplification consisting of 1 min at 95°C, 1 min at 54°C and 1 min at 72°C and 10 min at 72°C for the final extension. DNA fragments were analysed by electrophoresis in a 2% agarose gel at 100 V for 1 h in 1X TAE [40 mM Tris–HCl (pH8.3), 2 mM acetate and 1 mM EDTA] containing 0.05 mg/L ethidium bromide. Primer name Primer Sequences (5'-3') Product Size(bp) Reference  QnrAm-F  F AGAGGATTTCTCGCCAGG 580 Cattoir et al.,2007   QnrAm-R R TGCCAGGCACAGATCTTGAC Cattoir et al.,2007   QnrBm-F  F GGMATHGAAATTCGCCACTG 264 Cattoir et al.,2007   QnrBm- R R TTTGCYGYYCGCCAGTCGAA Cattoir et al.,2007   QnrSm-F  F GCAAGTTCATTGAACAGGGT 428 Cattoir et al.,2007   QnrSm-R R TCTAAACCGTCGAGTTCGGCG Cattoir et al.,2007  Primers for Detection of Quinolones Resistant genes (QnrA, QnrB, QnrS) M=A or C; H=A or C or T; Y=C or T.  RESULTS A total of  316 non-duplicate samples from various clinical of different patients were randomly selected and examined for detection of Gram negative bacteria .These clinical samples included wound swab(n=56, 17.7%),  burn swab (n=52,16.4%  ), ear swab (n=87,27.5% ) sputum (n=34, 10.7%), stool samples (n=44,13.9%)  urine from patients who were suffering from symptoms and signs of urinary tract infection (n= 43, 13.6%),of  316 samples   from different sources of clinical cases were founded   94 isolates of Gram negative bacteria , out of these  27 (28.72%) were E. coli , 12 (12.76%) Klebsiella spp , 3 ( 3.19 %) were  Enterobacter spp, 2 (2.12%) were Serrtia spp, 5 (5.31) were Proteus spp, 26 (27.65) were Pseudomonas spp,13 ( 13.82%) were Acinetobacter spp and 6 (6.38%) were Aeromonas spp. All the Gram negative isolates (n=94) were screened against seventeen antimicrobial agents belonging to several  structurally  diverse classes and the results showed that isolates varied in their resistance and sensitivity to the antibiotics . The amplification products were   identified as qnr-positive from their sizes in stained agarose gels . Overall, qnr-genes were identified in 28/94 (29.78%) of all clinical isolates. The results of screened for quinolones-resistance genes gave 25 positive results for qnrB that equal to target (264 bp) product size. While 9 positive results for qnrS that equal to target (428 bp) product size, but  qnrA gene was not detected in any of the clinical isolates as found in (Figure 1). Table (1): Number and Percentage of  bacterial isolation from clinical samples. Source of samples and specimens cases  positive cases % negative cases % Ear swab 87 10 11.49% 77 88.51% Urine samples 43 22 51.1% 21 48.9% Wound (pus) swabs 56 21 37.5% 35 62.5% Burn swab 52 21 40.38% 31 59.62% Sputum samples 34 10 29.4% 24 70.6% Stool specimens 44 10 22.72% 34 77.27% Total 316 94    222    
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Table ( 2 ) Antibiotic susceptibility patterns in all Gram negative isolates (n=94). Antibiotics S % I % R % Amikacin 63 67.02% 8 8.51% 23 24.46% Amoxicillin 0 0% 0 0% 94 100% Amoxicillin- clavulanic acid 15 15.95% 16 17.02% 63 67.02% Aztreonam 7 7.44% 13 13.82% 74 78.72% Carbencillin  5 5.31% 6 6.38% 83 88.29% Cefotaxime 12 12.76% 17 18.08% 65 69.14% Ceftazidime  26 27.65% 5 5.31% 63 67.02% Ceftriaxone 18 19.14% 10 10.63% 66 70.21% Ciprofloxacin  57 60.63% 8 8.51% 29 30.85% Gentamicin 28 29.78% 11 11.7% 55 58.51% Imipenem 68 72.34% 6 6.38% 20 21.27% Meropenem 73 77.65% 4 4.25% 17 18.08% Naldixic acid 19 20.21 % 8 8.51% 67 71.27% Netilmicin 68 72.34% 4 4.25% 22 23.40% Nitrofurantion 30 31.91% 4 4.25% 60 63.82% Norfloxacin 56 59.57% 5 5.31% 33 35.10% Ticarcillin 2 2.12% 4 4.25% 88 93.61%  Table (3): Distribution of quinolones-resistance genes (qnrA, qnrB, and qnrS genes) among   Gram negative isolates.   Isolated organism No. of   isolates qnrA qnrB qnrS qnrB + qnrS Escherichia coli 27 0 5 4 3 Klebsiella pneumoniae 12 0 10 0 0 Serratia marcescens 2 0 2 1 1 Pseudomonas aeruginosa 26 0 2 0 0 Proteus mirabilis 5 0 0 0 0 Aeromonas  hydrophila 6 0 0 0 0 Acintobacter  baumannii 13 0 6 6 4 Enterobacter aerogenes 3 0 0 0 0 Total 94 0 25 11 8  
 Figure (1): Ethidium bromide-stained agarose gel of multiplex PCR amplified products from extracted Gram negative isolates DNA amplified with primers for quinolones-resistance (qnrA, qnrB  and qnrS genes) .lane (L), DNA molecular size marker (2Kb ladder); lane (5e,19e,18w and 20b) shows positive results with qnrB (264pb); lane (9u,1w,9w,17w and 18b) shows positive results with qnrB(264pb) and qnrS (428pb); lane (6w and 10w) shows positive results with qnrS (428pb).  DISCUSSION Quinolones popularly used in both clinical and veterinary medicine. Their extensive use has resulted on bacteria 
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readily developing resistance to quinolones. However, two mechanisms of quinolone resistance has been established, alterations in site of action of quinolones, and decreased accumulation due to impermeability of the membrane and/or an overexpression of efflux pump systems to microorganisms. Lately, mobile elements have also been described that carrying the qnr gene, which confers resistance to quinolones (Joaquim , 2003). Also chromosomal location for qnr genes has been noted by some studies (Rodriguez-Martinez et al., 2006 and Cavaco et al., 2007). In this study, clinical isolates of Gram negative bacteria exhibits relatively low activities for the quinolones, with resistant to ciprofloxacin and norfloxacin, (30.85%) and (35.10%) respectively. Moreover, the percentage of quinolones-resistant in clinical isolates that found in this study is temperately lower than that found in several studies executed in Iraq between 2010-2013, in which resistance range for norfloxacin were 37.8-60% and 40.7-73.4% for ciprofloxacin (Al-Muhannak,2010; Al-Delaimi, 2012; Al-Shara,2013).  A probable reason for the variety of resistance rates in different studies was not understood, but it possibly reflect the amount of antimicrobial that used in various settings. The study prospect that quinolones susceptibility among clinical isolates of Gram negative bacteria appears to be decreasing in Iraq, perhaps due to increasing or cumulative quinolones use and the deficit of adherence to approved infection control practices by hospitals or may be quinolones-resistant isolates are more easily spread in hospitals and community. While, the resistance rates to quinolone antibiotics are higher in other part of the world compared to those in present study. For example, ciprofloxacin resistance more than 50% in Italy (Blandino et al ., 2004). But the quinolone resistance is emerging in Gram-negative pathogens, as noted in 2009 by the European Antimicrobial Resistance Surveillance Network that more than 20% of invasive Escherichia coli isolates have resistant to quinolones in Europe. In Spain, Hungary, Portugal, Cyprus and Bulgaria the resistance rates exceeded 25% (European Antimicrobial Resistance Surveillance database,(2009). Ling et al., (2006) noted that, the levels of quinolone resistance in clinical E. coli isolates has been noted at 40% in Hong Kong .Qnr determinants have been identified global from America, Europe, Africa, and Asia (Nordmann and Poirel. 2005 and Touati et al. 2008). They have been detected in a series of Enterobacteriaceae species, including E. coli, Enterobacter spp, Klebsiella spp, Salmonella spp, Providencia stuartii, Proteus mirabilis, and Serratia marcescens (Wang et al. 2003; Jeong et al. 2005; Mammeri et al. 2005; Nazic et al. 2005;Cambau et al. 2006 ). The screening from qnr genes (quinolone resistance determinants) demonstrates a (29.78%) 28/94 of clinical Gram negative isolates as found in (Table 3 and figure 1). These determinants was from isolates were resistant to naldixic acid, norfloxacin and ciprofloxacin. Overall the results of screened for quinolones-resistance genes gave 25 positive results for qnrB, while 11 positive results for qnrS but qnrA gene was not detected in any of the clinical isolates, 8 of all positive isolates had both qnrB and qnrS genes. However, high detections of qnr genes in Gram negative bacteria was noted in several parts of the world like Spain (5 %) (Lavilla et al. 2008), China (8 %) (Jiang et al. 2008) and USA (15 %) (Robicsek et al. 2006 ). The qnr genes were detected in six clinical isolates of E. coli and ten clinical isolates of Klebsiella spp. The higher prevalence of qnr genes in Klebsiella spp isolates than in E. coli isolates was also observing in other studies conducted in USA (Robiscek et al. 2006), Spain (Lavilla et al. 2008), and lately China (Jiang et al. 2008).  REFERENCES  Al-Delaimi M S (2012).Antimicrobial activity of black seed oil and water extract on multidrug resistant pseudomonas aeruginosa. J. of university of Anbar for pure science., 6(3). Al-Muhannak F H (2010). Spread of Some Extended-Spectrum Beta-Lactamases in Clinical Isolates of Gram-Negative Bacilli in Najaf. M.Sc.Thesis. College of Medicine. University of Kufa. Al-Shara J M R (2013). Phenotypic and molecular detecting of carbepenem resistant pseudomonas aeruginosa in Najaf Hospitals.Ph.D.Thesis.Faculty of Science.University of Kufa. Bauer A W , Kirby W M M, Sherris J S and Turk M (1966).Antibiotic susceptibility testing by a standardized single disk method .Amer. J. Clinic. Pathol., 45:493-496. Blandino G, Marchese A, Ardito F, Fadda G and Fontana R.(2004). Antimicrobial susceptibility profiles of Pseudomonas aeruginosa and Staphylococcus aureus isolated in Italy from patients with hospital acquired infections. Int. J. Antimicrob. Agents., 24:515-518. Cambau E, Lascols C ,Sougakoff W, Babear C, Bonnet R, Cavallo J-D, Gutmann L,Ploy M-C,Jerlier V, Soussy C-J. and Robert J. (2006). Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002–2005. Clin Microbiol Rev.,12: 1013–1020. Cattoir V, Poirel L and Nordmann P. (2007). Plasmid-Mediated Quinolone Resistance Determinant QnrB4 in France from an Enterobacter cloacae Clinical Isolate Coexpressing a QnrS1 Determinant. Antimicrob Agents Chemother., 51:2652-2653. Cattoir V, Poirel L, Aubert C, Soussy C J and Nordman P. (2008). Unexpected occurrence of plasmid-mediated quinolone resistance determinants in environmental Aeromonas spp. Emerg Infect Dis., 14: 231–237. Cavaco L M, Hansen D S, Friis-Møller A, Aarestrup F M, Hasman H and Frimodt-Møller N. ( 2007). First 
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